Pivikto 200 mg/50 mg Tablet 28's

Pivikto 200 mg/50 mg Tablet belongs to a class of kinase inhibitors. It is used in conjunction with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer.

Pivikto 200 mg/50 mg Tablet contains Alpelisib. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.

To treat your condition effectually, continue using Pivikto 200 mg/50 mg Tablet for as long as your doctor has prescribed it. The most common side effects include rash, decreased appetite, weight loss, nausea, mouth sores, hair loss, tiredness and weakness, vomiting, changes in certain blood tests, allergic reactions, skin reactions, high blood sugar levels, lung problems, and diarrhea. You should talk to your doctor if you persistently experience these side effects.

Avoid taking Pivikto 200 mg/50 mg Tablet if you are allergic to it. It is not recommended for use in pregnancy. Lactating women do not breastfeed during treatment with Pivikto 200 mg/50 mg Tablet and for one week after the last dose. Alcohol should be avoided during treatment with this medicine. Safety and effectiveness in children have not been established.

Pivikto 200 mg/50 mg Tablet is used in the treatment of Advanced or metastatic breast cancer. The detailed uses of Pivikto 200 mg/50 mg Tablet are as follows:

• Advanced or metastatic breast cancer: Pivikto 200 mg/50 mg Tablet is used for hormone receptor (HR)-positive, HER2-negative, and PIK3CA-mutated breast cancer that has progressed or spread to other parts of the body. It is typically used in combination with fulvestrant, a hormonal therapy, especially in patients who have already undergone endocrine-based treatment.
• Targeted cancer therapy: Pivikto 200 mg/50 mg Tablet works by inhibiting the PI3K (phosphatidylinositol-3-kinase) pathway, which is often overactive in certain cancers. By blocking this pathway, it helps slow down or stop the growth of cancer cells.

• Take Pivikto 200 mg/50 mg Tablet with meals, as it helps with absorption and reducing stomach upset.
• Pivikto 200 mg/50 mg Tablet is usually taken once daily at the same time. However, follow the recommended dose and timing as directed by your doctor for optimal results.
• Swallow the tablet as a whole with water.
• Do not crush, chew or break it.

Pivikto 200 mg/50 mg Tablet contains Alpelisib, which belongs to a class of kinase inhibitors. It is used in conjunction with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.

It is not advised during pregnancy, nursing, or for children or young adults under 18. Before taking the Pivikto 200 mg/50 mg Tablet , inform your doctor about all your medical conditions (especially lung infections, diarrhoea, diabetics, kidney or liver impairment), sensitivities or allergic conditions, and all medications you use. Consult your doctor right away if you become pregnant while taking Pivikto 200 mg/50 mg Tablet . Exposure of an unborn child to this medication could cause congenital disabilities, so you should not become pregnant or father a child while on this medication. Effective birth control is required throughout treatment and at least one week after treatment. You should not breastfeed while taking this medication for two weeks after your last dose.